coenzyme-q10 and Myocarditis

Acute viral myocarditis is an inflammatory disease with global impact. Although it may resolve spontaneously, its course is not easily predicted, and there is a paucity of specific treatment options available with proven efficacy. Coenzyme Q10 (CQ10) and trimetazidine possess antioxidant and antiinflammatory effects.. We examined the therapeutic efficacy of these agents in acute viral myocarditis both individually and in combination. Patients were blinded and randomized to receive CQ10 (n = 42), trimetazidine (n = 39), or CQ10 + trimetazidine (n = 43) treatment.. Serum inflammatory and oxidative stress marker and myocardial enzyme levels, and heart function were measured. Both CQ10 and trimetazidine decreased inflammatory and oxidative stress biomarker levels compared with baseline measurements. However, combination therapy with CQ10 and trimetazidine showed a significantly more powerful effect not only on markers of inflammation and oxidative stress, but also on left ventricular systolic function and troponin, compared with either treatment alone.. This study confirmed the beneficial effect of CQ10 and trimetazidine individually, but demonstrated a superior effect of combining the therapies on cardiac left ventricular ejection fraction, and biochemical markers of myocardial damage in acute viral myocarditis.

Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Antioxidants; Biomarkers; China; Drug Therapy, Combination; Female; Humans; Inflammation Mediators; Male; Myocarditis; Oxidative Stress; Recovery of Function; Stroke Volume; Systole; Time Factors; Treatment Outcome; Trimetazidine; Troponin; Ubiquinone; Ventricular Function, Left; Young Adult

We studied the effects of coenzyme Q10 (CoQ10) on mice with acute myocarditis inoculated with the encephalomyocarditis (EMC) virus with the analysis of indices of effects of oxidative injury and DNA damage in the myocardium. The mice were treated as follows: CoQ10 group (n = 118); CoQ10 1.0 mg (0.1 mL) x 2/d (0.1 mg/g/d), control group (n = 128); sham-liquid 0.1 mL x 2/d. The mice were injected intraperitoneally 1 day before and daily for 12 days after EMC virus inoculation. The expression of thioredoxin, a marker of oxidative stress overload, as well as 8-hydroxy-2'-deoxyguanosine, an established marker of DNA damage, in the myocardium was investigated. The survival rate was significantly higher (P < 0.01) in the CoQ10 group (46.8%, 29/62) than in the control group (14.3%, 10/70). There were significant increases of CoQ9 and CoQ10 in the heart, which are the biologically active forms of CoQ in mice, and significant decrease of serum creatine kinase (CK)-MB in the CoQ10 group as compared with the control group. Histologic examination showed that the severity of myocarditis was less severe (P < 0.01) in the CoQ10 group than in the control group. In addition, the up-regulation of myocardial thioredoxin with DNA damage, which was induced by the inflammatory stimuli by the virus, was suppressed by the CoQ10 treatment, which may reflect the anti-oxidant effects of CoQ10 treatment. Thus, pretreatment with CoQ10 may reduce the severity of viral myocarditis in mice associated with decreasing oxidative stress in the condition.

Topics: Animals; Antioxidants; Coenzymes; Mice; Mice, Inbred DBA; Myocarditis; Ubiquinone

To clarify the effects of Astragalus Membranaceus (AM) combined with taurine and/or coenzyme Q10(CoQ10) on coxsackievirus B3 (CVB3) murine myocarditis.. Viral myocarditis model was created by intraperitoneal inoculation with CVB3 solution and were treated by saline, AM, taurine, CoQ10, AM + taurine, AM + CoQ10, AM + taurine + CoQ10, respectively. The mortality, ECG, CVB3-RNA in myocardium and myocardial histopathologic changes were observed.. AM combined with taurine and CoQ10 could significantly reduce the mortality of the mice and the incidence of abnormal ECG at acute stage. CVB3-RNA was significantly reduced in AM treated group, especially in AM + taurine group. No anti-virus effect was found in CoQ10 group. All drugs could lighten myocardial histopathologic changes and the effect could be enhanced by combined treatment.. AM, taurine and CoQ10 have some curative effects on CVB3 murine myocarditis, AM combined with taurine and CoQ10 is the best.

Topics: Animals; Astragalus propinquus; Coenzymes; Coxsackievirus Infections; Drug Therapy, Combination; Drugs, Chinese Herbal; Enterovirus B, Human; Male; Mice; Mice, Inbred BALB C; Myocarditis; Random Allocation; Taurine; Ubiquinone

We studied the effects of Coenzyme Q10 (CoQ10) on DBA/2 mice inoculated with the M variant of encephalomyocarditis virus. The mice were treated as follows: 1) CoQ group (n = 49); CoQ10 1.0 mg (0.1 ml) X 2/day (0.1 mg/g/day), 2) control group (n = 55); sham-liquid 0.1 ml X 2/day. These treatments were intraperitoneally performed every day on days -1 to 12. In both groups, we determined the heart and serum contents of CoQ9 and CoQ10, which are the biologically active forms of CoQ in mice, in the mice killed on days 3-4 and 7. There was no significant change in the cumulative incidence of myocarditis in both groups. The survival rate was significantly higher on days 5-12 in the CoQ group than in the control group. There were significant increases of CoQ9 content on days 3-4, and CoQ10 content on days 3-4 and 7, in the heart in the CoQ group as compared with the control group. There was no significant change in the serum content of CoQ9 in both groups. The marked increase of the serum CoQ10 content seen in the CoQ group was due to the results of the exogenous administration of CoQ10. Thus, it may be concluded that CoQ10 may have a protective effect against viral myocarditis in man, in whom CoQ10 is only an active form of CoQ.

Topics: Animals; Coenzymes; Encephalomyocarditis virus; Enterovirus Infections; Mice; Mice, Inbred DBA; Myocarditis; Myocardium; Ubiquinone